Bolt Biotherapeutics’ trastuzumab biosimilar conjugated with TLR7/8 via a non-cleavable linker was granted FDA orphan designation as a treatment of gastric cancer, including gastroesophageal junction cancer, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BOLT:
- Bolt Biotherapeutics announces issuance of U.S. patent covering BDC-3042
- Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
- Bolt Biotherapeutics to Participate in September Investor Conferences
- Bolt Biotherapeutics price target lowered to $6 from $7 at Stifel
- Bolt Biotherapeutics reports Q2 EPS (48c), consensus (49c)
